SUPN
Supernus Pharmaceuticals Stock Analysis
AI Rating
- Quality4/10
- Growth↓ 4/10
- Momentum↑ 7/10
SUPN Growth
- Revenue Y/Y↓ 4.54%
- EPS Y/Y↓ -130.56%
- FCF Y/Y↓ -58.87%
SUPN Profitability
- Gross margin ↑ 88.60%
- EPS margin↓ -2.80%
- ROIC↓ -6.10%
SUPN Risk
- Debt / Equity↓ 0.0
- Debt / FCF↓ 0.0
- Interest coverage↓ NA
Supernus Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.